Introduction
Intraoperative neuromonitoring (IONM) has improved the safety of neurosurgical procedures but relies on avoiding volatile anaesthesia. Total intravenous anaesthesia (TIVA) for patients younger than one year is not possible using existing target-controlled infusion (TCI) devices. Applying the TCI pumps' pharmacokinetic (PK) models outside of their reference populations will lead to inaccurate dosing and is not recommended. PK models applicable for infants have been described and can be applied clinically using pharmacokinetic simulation software and advisory displays (e.g. Stelsim 1 ). The technique comprises tracking a manually controlled infusion regimen in real time while displaying the estimated blood and effect-site concentrations, thereby assisting the clinician to maintain stable drug concentrations and stable drug effect. The method also enables titration of drug dosage to the patient requirements and facilitates timely emergence and extubation. We call the technique "target guided infusion (TGI)".
Propofol and remifentanil are the hypnotic and opioid of choice for TIVA in this age group for inter alia the rapidity of their onset and offset. We present a case requiring IONM and TIVA that involved an added challenge, namely unavailability of the opioid remifentanil. Surgical resection with intraoperative neuromonitoring (IONM) was planned. Considering that remifentanil was unavailable in our hospital at that time due to a nationwide shortage, a decision
Case report
We present an uncommon case of limited dorsal myeloschisis in a 3-month-old infant requiring repair guided by intraoperative neuromonitoring (IONM) and therefore avoidance of volatile anaesthetic agents. The case presented challenges in positioning, airway management, a lack of age appropriate pharmacokinetic models in target-controlled infusion (TCI) syringe pumps and unavailability of remifentanil, considered to be an essential drug in this setting. We overcame these challenges using manually controlled infusions of propofol and alfentanil guided by pharmacokinetic simulation software (Stelsim).
was made to administer TIVA by TGI using propofol and alfentanil to facilitate IONM.
Because no appropriate pharmacokinetic (PK) models exist within currently available infusion pumps, we utilised Stelsim 1 (version 2.04, Revision 1, August 2012) pharmacokinetic simulation software to guide both infusions. We pre-planned an initial bolus-and-infusion regimen calculated to rapidly achieve and maintain propofol and alfentanil effect-site concentrations of 3 µg/mL and 90 ng/mL respectively, employing the pharmacokinetic parameter sets of Eleveld 2 for propofol and Goresky 3 for alfentanil (Table I) .
The dose regimens were planned as follows. Stelsim TCI simulations were conducted, targeting effect sites of 90 ng/mL for alfentanil and 3 µg/mL for propofol. From the simulations we obtained the initial loading doses to be administered, as well as the subsequent doses to be administered by infusion during the first ten minutes. The pre-calculated initial doses were thus administered to the patient manually, while the infusions were begun as indicated in Table II and A grade 1 laryngoscopy view was obtained with a Macintosh 1 blade and the cords were topicalised with 2% lignocaine to facilitate intubation while avoiding muscle relaxation. Arterial and central venous lines and a urinary catheter were inserted. The baby was turned to the prone position with its face supported on its forehead, cheeks and chin in the centre of a hollow foam support used for intubation and all pressure points were addressed. Prior to each anticipated increase in surgical stimulus during surgery, an alfentanil bolus of between 5-20 ug/kg was administered and recorded in Stelsim to maintain an accurate estimate of the predicted Ce. Infusion rates were adjusted according to clinical response (heart rate, blood pressure, effect on evoked potentials) to maintain appropriate Ce's 6, 7 for surgical anaesthesia as predicted by Stelsim. Satisfactory somatosensory and motor-evoked potentials were achieved throughout the period of IONM.
Blood loss was approximately 100 mL. The lowest recorded haemoglobin concentration was 7.5 g/dL and 130 mL of crossmatched blood was transfused. At the conclusion of surgery, during closure of the subcutaneous layers, propofol and alfentanil Ce targets were lowered to 2.0 ug/mL and 80 ng/ mL respectively in order to decrease the time to recovery. This involved slowing/stopping the syringe pumps and restarting them at reduced infusion rates as the simulated effect-site drug concentrations approached the reduced targets. After application of wound dressings both infusions were stopped. Spontaneous breathing returned soon after repositioning in the supine position. Intravenous morphine 0.5 mg and clonidine 5 µg were administered, and the baby's trachea was extubated while on the operating table four minutes prior to the predicted recovery time.
He appeared comfortable with normal gross motor function noted in all four limbs and was transferred to the paediatric intensive care unit while receiving nasal prong oxygen. Total procedure time was 3 hours 45 minutes. Figure 3 portrays the pump rates and the simulated drug concentrations. Total doses administered were propofol 148 mg, alfentanil 1033 µg.
Discussion
Cervical limited dorsal myeloschisis (CLDM) is rare. There may be tethering to the spinal cord and 50% may involve neurological or orthopaedic anomalies, including hydrocephalus associated with Chiari II malformation 8 and occult thoracolumbar spina bifida. The optimal timing for surgery is between six months and 1 year, unless neurological deterioration mandates earlier intervention. Surgery is performed in the prone position and involves laminectomy, intra-dural exploration and resection of septae and tethering bands. Intraoperative neuromonitoring (IONM) enhances surgical safety. IONM includes motor evoked potential (MEPs) monitoring, somatosensory evoked potential (SSEPs) monitoring and mapping of compound motor action potentials (CMAPs). Myelination is incomplete in children younger than three years, and it is important to avoid drugs that may impede signal conduction. Volatile anaesthetics and possibly dexmedetomidine 9-12 may affect IONM, and therefore TIVA is the technique of choice. [13] [14] [15] [16] Muscle relaxants should be The requirement for TIVA in this patient presented two challenges; unavailability of remifentanil and TCI-pumps without ageappropriate PK models for sufentanil or alfentanil. There are no sufentanil PK studies available for infants aged less than one year undergoing non-cardiac surgery. The "Goresky" PK parameter-set for alfentanil 3 is suitable for children aged between three months and 14 years. Stelsim simulations indicated that alfentanil would be suitable and that recovery would not be prolonged, even after prolonged infusions.
"Paedfusor" 4 and "Kataria" 18 paediatric propofol models used in commercially available TCI pumps have lower age limits of one and three years respectively. Using a PK model outside of its intended age group can result in significant dosage error 19 (see Table I ), as propofol pharmacokinetics vary significantly during the first 12 months. 20 We used the recently published "Eleveld" broad application model 2 which includes infant data. The model employs a maturation algorithm in addition to allometric scaling, thereby extending its lower age limit to infants and neonates below one year. The Eleveld model provides significant advantages over existing paediatric propofol models.
Similar to end-tidal volatile agent concentrations, advisory displays of expected plasma concentrations of infused intravenous drugs enable anaesthesiologists to fine-tune dosage according to patient requirements. 21 Unlike end-tidal monitoring, patients' real plasma concentrations of infused drug will always differ somewhat from the simulation's display. Nevertheless, absolute prediction errors of 20% to 30% are clinically satisfactory. [22] [23] [24] TCI and TGI dose regimens are based on pharmacokinetic principles that enable clinicians to establish patients' drug concentrations within desired therapeutic windows and from there to titrate administration according to patient requirements. Useful guidelines for target concentrations have been published for individual drugs 6 as well as for propofolopioid combinations. 7 Several other TGI advisory display systems with larger drug libraries and up-to-date PK models are available, for example TIVA Trainer (Windows), iTIVA and TIVA Manager (Android). We used Stelsim because users can utilise any combination of PK parameters for any drug, since Stelsim allows users to manually program the pharmacokinetic parameters of drugs not contained in the software's original drug library. It is noteworthy that none of the newer models have been validated externally.
Recent developments include portrayal of drug-drug interactions based on response surface modelling. 25 Two systems are commercially available, the Smart Pilot View (Drager, Lubeck, Germany) and the GE Navigator (GE Healthcare, Helsinki, Finland). Struys and co-workers provide a brief review of these advanced advisory display systems. 26
Conclusion
Unavailability of essential drugs is a reality in developing countries such as South Africa. Difficulties in providing TIVA may be compounded by a non-availability of appropriate PK parameter-sets for patients at the extremes of age and size on TCI devices. This case illustrates how alternate drugs and advisory displays can be employed effectively. It also exemplifies the challenges of airway management and positioning of a small patient with a large CLDM.
